IN B001
Alternative Names: CJ-40010; EV71/CVA16 bivalent vaccine - HK inno.N; IN-B001Latest Information Update: 28 Jan 2023
Price :
$50 *
At a glance
- Originator CJ HealthCare
- Developer HK inno.N
- Class Enterovirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Coxsackievirus infections
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for phase-I development in Coxsackievirus-infections(Prevention) in South Korea
- 20 Nov 2020 HK inno.N Corporation plans a phase I trial for Coxsackievirus infections (Prevention) in South Korea in December 2020 (NCT04637919)
- 18 Jun 2020 CJ HealthCare is now called HK inno.N